PTHS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pelthos Therapeutics Inc. (PTHS) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has promising products and analyst ratings are favorable, the lack of significant recent positive catalysts, neutral trading sentiment, and no clear technical signals suggest waiting for more clarity or a stronger entry point.
The MACD is positive and expanding, indicating a potential upward momentum. RSI is neutral at 54.249, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at 24.085 and 25.621, while support levels are at 19.111 and 17.575.
The company has a strong product pipeline, including Zelsuvmi, which addresses a large, underserved market. Revenue growth is steady, and gross margin is solid at 59.56%.
The company is still operating at a net loss with negative EPS (-5.3). Insider and hedge fund trading sentiment is neutral, indicating no strong confidence from key stakeholders. No recent news or significant events to drive immediate price action.
In Q3 2025, revenue remained flat YoY at $7.406M. However, net income improved significantly, up 858.19% YoY, though it remains negative at -$16.238M. EPS improved by 80.89% YoY but is still negative. Gross margin is stable at 59.56%.
Analysts are optimistic with multiple Buy ratings and price targets between $50 and $60. Recent updates reflect adjustments for seasonality and product launch challenges, but long-term views remain positive.
